Compromiso esofágico en pacientes con pemfigo de membaranas mucosas...

Original Article

Oesophageal involvement in 26 consecutive patients with mucous membrane pemphigoid

Authors

• O. Zehou,

• J.-J. Raynaud,

• C. Le Roux-Villet,

• M. Alexandre,

• G. Airinei,

• F. Pascal,

• M. Heller,

• N. Lièvre,

• L. Laroche,

• F. Caux,

• R. Benamouzig,

• C. Prost-Squarcioni

• Accepted manuscript online: 18 April 2017Full publication history
• DOI: 10.1111/bjd.15592  View/save citation
• Cited by (CrossRef): 0 articlesCheck for updates 

• This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bjd.15592

Summary

Background

Oesophageal involvement of mucous membrane pemphigoid (MMP) has not yet been thoroughly described.

Objectives

This study was undertaken to systematically characterise the endoscopic lesions of a series of patients with oesophageal symptoms seen in a referral centre for autoimmune bullous diseases.

Methods

Clinical, endoscopic and immunological findings of consecutively referred MMP patients with oesophageal involvement, systemic and endoscopic treatments and follow-up, are described.

Results

Among 477 consecutive MMP patients consulting between 2002 and 2012, 26 (6%) had symptomatic oesophageal involvement. Dysphagia, observed in 23 (88%) patients, was the most frequent symptom. Oesophageal symptoms could be the first sign of MMP. Patients with oesophageal involvement had a mean of three other involved sites. At initial oesophageal endoscopy, 17/26 patients had active lesions (intact bullae, erosions and/or erythema), 15 had stricture(s) and 12 had other cicatricial lesions. Systemic therapy alone achieved oesophageal symptom relief for five patients. Dilatation was combined with systemic therapy for 12 patients and was successful in nine; one perforation occurred.

Conclusion

Symptomatic oesophageal involvement affected 6% of MMP patients. Dermatologists and gastroenterologists should be aware of these mucocutaneous diseases and their oesophageal involvement, as it could lead to earlier diagnosis and better care. Oesophageal dilatation could be a therapeutic option for symptomatic stricture not relieved by optimized systemic therapy alone.

This article is protected by copyright. All rights reserved.